Second, when hu - PBMCs were treated with the IL - 15 superagonist in vitro and subsequently incubated with K562 cells, a well - characterized NK target cell population, the treated NK cells showed increased Cd69 and CD107a expression, markers
for activation and
degranulation, respectively, compared to untreated hu - PBMCs.